<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://www.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Wed, 13 May 2026 06:07:55 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://www.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Lucid Capital Markets Starts NRX Pharma (NXRP) at Buy</title>
   <link>http://www.streetinsider.com/New+Coverage/Lucid+Capital+Markets+Starts+NRX+Pharma+%28NXRP%29+at+Buy/26481100.html</link>
   <description>&lt;p&gt;Lucid Capital Markets analyst Elemer Piros initiates coverage on NRX Pharma (: NXRP) with a Buy rating and a price target of $49.00.&lt;/p&gt;&lt;p&gt;The analyst comments &quot;We are initiating coverage of NRx Pharnaceuticals, Inc. (NRXP) with a Buy rating and a 12- month price target of $49/share. NRx is about to enter the ~$1.5B North American ketamine market with a proprietary generic and a branded formulation.&quot;&lt;/p&gt;&lt;p&gt;For an analyst ratings summary and ratings history on NRX Pharma &lt;a href=&quot;http://www.streetinsider.com/rating_history.php?q=NXRP&quot;&gt;click here&lt;/a&gt;. For more ratings news on NRX Pharma &lt;a href=&quot;http://www.streetinsider.com/stock_lookup_news.php?q=NXRP&amp;amp;type=analyst&quot;&gt;click here&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Shares of NRX Pharma closed at $ yesterday.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/New+Coverage/Lucid+Capital+Markets+Starts+NRX+Pharma+%28NXRP%29+at+Buy/26481100.html</guid>
   <pubDate>Wed, 13 May 2026 06:07:55 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">NXRP</category>
   	  </item>
  <item>
   <title>Lucid Capital Markets Starts NRX Pharma (NXRP) at Buy</title>
   <link>http://www.streetinsider.com/Analyst+Comments/Lucid+Capital+Markets+Starts+NRX+Pharma+%28NXRP%29+at+Buy/26481100.html</link>
   <description>&lt;p&gt;Lucid Capital Markets analyst Elemer Piros initiates coverage on NRX Pharma (: NXRP) with a Buy rating and a price target of $49.00.&lt;/p&gt;&lt;p&gt;The analyst comments &quot;We are initiating coverage of NRx Pharnaceuticals, Inc. (NRXP) with a Buy rating and a 12- month price target of $49/share. NRx is about to enter the ~$1.5B North American ketamine market with a proprietary generic and a branded formulation.&quot;&lt;/p&gt;&lt;p&gt;For an analyst ratings summary and ratings history on NRX Pharma &lt;a href=&quot;http://www.streetinsider.com/rating_history.php?q=NXRP&quot;&gt;click here&lt;/a&gt;. For more ratings news on NRX Pharma &lt;a href=&quot;http://www.streetinsider.com/stock_lookup_news.php?q=NXRP&amp;amp;type=analyst&quot;&gt;click here&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Shares of NRX Pharma closed at $ yesterday.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/Lucid+Capital+Markets+Starts+NRX+Pharma+%28NXRP%29+at+Buy/26481100.html</guid>
   <pubDate>Wed, 13 May 2026 06:07:55 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">NXRP</category>
   	  </item>
 </channel>
</rss>
